DeepMatcher® Success Stories
The Superiority of Syntekabio's Flexible Molecular Docking (FMD) Approach in Drug Discovery
Syntekabio’s AI-driven DeepMatcher® platform leverages Flexible Molecular Docking (FMD) to offer substantial improvements over traditional Rigid Molecular Docking (RMD). By incorporating protein flexibility, FMD enhances the accuracy of pose predictions, increases the likelihood of discovering viable drug candidates, and can potentially shorten development timelines, providing a significant edge in drug discovery.
Enhanced Accuracy in Pose Predictions: FMD accounts for the natural flexibility of proteins, leading to more accurate pose predictions, which can achieve accuracy levels between 80-95%. This is a notable improvement over RMD, which typically offers accuracy rates of 50-75%. This higher precision aids in more confidently identifying potential drug candidates.
Increased Likelihood of Viable Hits: FMD’s flexible approach expands the opportunity to identify promising hits and leads, often resulting in 6-8 good hits and 3-4 optimized leads. In comparison, RMD tends to produce fewer hits, often only 1-2, due to its rigid nature. This broader range of potential candidates early in the process enhances the chances of finding effective therapies.
Potential for Faster Development: FMD has the capability to reduce the overall timeline for drug discovery, potentially shortening the process from the typical 5-7 years associated with RMD to as little as 2 years. This accelerated timeline can bring viable drug candidates to the preclinical stage more quickly, enhancing the efficiency of the drug development pipeline.
DeepMatcher® Success Stories
The Superiority of Syntekabio's Flexible Molecular Docking (FMD) Approach in Drug Discovery
Syntekabio’s AI-driven DeepMatcher® platform leverages Flexible Molecular Docking (FMD) to offer substantial improvements over traditional Rigid Molecular Docking (RMD). By incorporating protein flexibility, FMD enhances the accuracy of pose predictions, increases the likelihood of discovering viable drug candidates, and can potentially shorten development timelines, providing a significant edge in drug discovery.
Enhanced Accuracy in Pose Predictions: FMD accounts for the natural flexibility of proteins, leading to more accurate pose predictions, which can achieve accuracy levels between 80-95%. This is a notable improvement over RMD, which typically offers accuracy rates of 50-75%. This higher precision aids in more confidently identifying potential drug candidates.
Increased Likelihood of Viable Hits: FMD’s flexible approach expands the opportunity to identify promising hits and leads, often resulting in 6-8 good hits and 3-4 optimized leads. In comparison, RMD tends to produce fewer hits, often only 1-2, due to its rigid nature. This broader range of potential candidates early in the process enhances the chances of finding effective therapies.
Potential for Faster Development: FMD has the capability to reduce the overall timeline for drug discovery, potentially shortening the process from the typical 5-7 years associated with RMD to as little as 2 years. This accelerated timeline can bring viable drug candidates to the preclinical stage more quickly, enhancing the efficiency of the drug development pipeline.
DeepMatcher® Success Stories
The Superiority of Syntekabio's Flexible Molecular Docking (FMD) Approach in Drug Discovery
Syntekabio’s AI-driven DeepMatcher® platform leverages Flexible Molecular Docking (FMD) to offer substantial improvements over traditional Rigid Molecular Docking (RMD). By incorporating protein flexibility, FMD enhances the accuracy of pose predictions, increases the likelihood of discovering viable drug candidates, and can potentially shorten development timelines, providing a significant edge in drug discovery.
Enhanced Accuracy in Pose Predictions: FMD accounts for the natural flexibility of proteins, leading to more accurate pose predictions, which can achieve accuracy levels between 80-95%. This is a notable improvement over RMD, which typically offers accuracy rates of 50-75%. This higher precision aids in more confidently identifying potential drug candidates.
Increased Likelihood of Viable Hits: FMD’s flexible approach expands the opportunity to identify promising hits and leads, often resulting in 6-8 good hits and 3-4 optimized leads. In comparison, RMD tends to produce fewer hits, often only 1-2, due to its rigid nature. This broader range of potential candidates early in the process enhances the chances of finding effective therapies.
Potential for Faster Development: FMD has the capability to reduce the overall timeline for drug discovery, potentially shortening the process from the typical 5-7 years associated with RMD to as little as 2 years. This accelerated timeline can bring viable drug candidates to the preclinical stage more quickly, enhancing the efficiency of the drug development pipeline.
DeepMatcher® Success Stories
The Superiority of Syntekabio's Flexible Molecular Docking (FMD) Approach in Drug Discovery
Syntekabio’s AI-driven DeepMatcher® platform leverages Flexible Molecular Docking (FMD) to offer substantial improvements over traditional Rigid Molecular Docking (RMD). By incorporating protein flexibility, FMD enhances the accuracy of pose predictions, increases the likelihood of discovering viable drug candidates, and can potentially shorten development timelines, providing a significant edge in drug discovery.
Enhanced Accuracy in Pose Predictions: FMD accounts for the natural flexibility of proteins, leading to more accurate pose predictions, which can achieve accuracy levels between 80-95%. This is a notable improvement over RMD, which typically offers accuracy rates of 50-75%. This higher precision aids in more confidently identifying potential drug candidates.
Increased Likelihood of Viable Hits: FMD’s flexible approach expands the opportunity to identify promising hits and leads, often resulting in 6-8 good hits and 3-4 optimized leads. In comparison, RMD tends to produce fewer hits, often only 1-2, due to its rigid nature. This broader range of potential candidates early in the process enhances the chances of finding effective therapies.
Potential for Faster Development: FMD has the capability to reduce the overall timeline for drug discovery, potentially shortening the process from the typical 5-7 years associated with RMD to as little as 2 years. This accelerated timeline can bring viable drug candidates to the preclinical stage more quickly, enhancing the efficiency of the drug development pipeline.
DeepMatcher® Success Stories
The Superiority of Syntekabio's Flexible Molecular Docking (FMD) Approach in Drug Discovery
Syntekabio’s AI-driven DeepMatcher® platform leverages Flexible Molecular Docking (FMD) to offer substantial improvements over traditional Rigid Molecular Docking (RMD). By incorporating protein flexibility, FMD enhances the accuracy of pose predictions, increases the likelihood of discovering viable drug candidates, and can potentially shorten development timelines, providing a significant edge in drug discovery.
Enhanced Accuracy in Pose Predictions: FMD accounts for the natural flexibility of proteins, leading to more accurate pose predictions, which can achieve accuracy levels between 80-95%. This is a notable improvement over RMD, which typically offers accuracy rates of 50-75%. This higher precision aids in more confidently identifying potential drug candidates.
Increased Likelihood of Viable Hits: FMD’s flexible approach expands the opportunity to identify promising hits and leads, often resulting in 6-8 good hits and 3-4 optimized leads. In comparison, RMD tends to produce fewer hits, often only 1-2, due to its rigid nature. This broader range of potential candidates early in the process enhances the chances of finding effective therapies.
Potential for Faster Development: FMD has the capability to reduce the overall timeline for drug discovery, potentially shortening the process from the typical 5-7 years associated with RMD to as little as 2 years. This accelerated timeline can bring viable drug candidates to the preclinical stage more quickly, enhancing the efficiency of the drug development pipeline.